Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Blood. 2016 Sep 29;128(13):1679-87. doi: 10.1182/blood-2016-05-636357. Epub 2016 Aug 9.
The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the current immune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.
多发性骨髓瘤的治疗在过去几十年中发生了重大变化，从主要基于烷化剂的化疗药物（疗效甚微）发展到更有效的药物，包括免疫调节剂和蛋白酶体抑制剂，这改变了该疾病的治疗格局。我们现在正进入一个新的时代，免疫疗法将越来越多地纳入标准治疗。本文讨论了目前批准的基于免疫的策略，以及正在积极研究的各种免疫方法，包括单克隆抗体、检查点抑制剂、疫苗和过继性 T 细胞疗法。
